FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

Alert on Abiomed Heart Pumps

FDA issues an early alert about a potentially high-risk problem involving certain heart pump components manufactured by Abiomed, warning that a malfun...

latest-news-card-1
Human Drugs

FDA Division of Applied Regulatory Science Releases Annual Report

CDER Division of Applied Regulatory Science (DARS) has published its 2025 Annual Report, highlighting significant research advances, collaborative sci...

latest-news-card-1
Human Drugs

Rep. Gottheimer Introduces 5 Bipartisan Rare Disease Bills

Rep. Josh Gottheimer introduces several bills to mark Rare Disease Week.

latest-news-card-1
Human Drugs

CDER Plans 81 New, Revised Guidances in 2026

FDA releases a list of 81 new and revised guidances in 12 categories that CDER plans to issue this calendar year.

latest-news-card-1
Human Drugs

5 CGMP Issues Cited in Ross Healthcare Inspection

FDA warns Ross Healthcare, in Lynden, WA, about CGMP violations in its production of finished drugs.

latest-news-card-1
Biologics

FDA Accepts Vanda BLA for Rare Skin Disorder Drug

FDA accepts for review a Vanda Pharmaceuticals BLA for imsidolimab, a potential new treatment for generalized pustular psoriasis.

latest-news-card-1
Human Drugs

Novo Nordisk Triple G Weight Loss Drug Shows Promise

Novo Nordisk reports favorable weight-loss data with its triple agonist UBT251 in a Phase 2 trial in China.

latest-news-card-1
Human Drugs

Immedica Gains Accelerated OK for Arginase 1 Deficiency Therapy

FDA grants Immedica Pharma an accelerated approval for its BLA for Loargys (pegzilarginase-nbln), the first therapy specifically designed to lower pla...

latest-news-card-1
Human Drugs

Beta Bionics Gets Warning on iLet Bionic Pancreas

FDA issues Beta Bionics a Warning Letter, citing wide-ranging quality system, complaint handling, reporting, and recall-related violations tied to the...

latest-news-card-1
Biologics

BioMarin Withdrawing Hemophilia A Gene Therapy

BioMarin decides to voluntarily withdraw from the market its Roctavian (valoctocogene roxaparvovec-rvox) gene therapy for treating adults with severe ...